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Abstract
Although there is an epidemic of NAFLD throughout the world, the management of 
NAFLD is not very satisfactory at the present time. Lifestyle modification is the main 
mode of therapy. Other modalities like pharmacotherapy and bariatric endoscopy or sur-
gery should be individualized. Various pharmacological agents are being investigated to 
optimize the treatment of NAFLD.
Keywords: nonalcoholic fatty liver disease, fatty liver, hepatic steatosis, nonalcoholic 
steatohepatitis, NASH, treatment of NAFLD
1. Introduction
When we consider the management of Nonalcoholic Fatty Liver Disease (NAFLD), two 
aspects should be considered. One is that it can be a part of the metabolic syndrome [1]. 
About 80% of patients with metabolic syndrome have NAFLD [2]. Although the prevalence 
of NAFLD is 20–40% in the general population, about 70% of type 2 diabetes mellitus [3] 
and 85% of patients with morbid obesity (BMI ≥ 40) have NAFLD [4]. In the general popula-
tion, 80% of patients with NAFLD are overweight and 20% of NAFLD patients have normal 
weight as per ultrasonography [5]. Another aspect is that it covers a spectrum of hepatic 
involvement as it progresses slowly from one stage to another. Initially, it starts as simple 
steatosis or benign fatty liver disease or nonalcoholic fatty liver (NAFL), where there is only 
macrovesicular hepatic steatosis (>5% of hepatocytes are affected) without any inflammation, 
hepatocellular injury or fibrosis [6]. The second phase is nonalcoholic steatohepatitis (NASH) 
where there is not only hepatic steatosis but also ballooning degeneration of hepatocytes and 
mixed inflammatory cells (lymphocytes, plasma cells, monocytes, neutrophils and eosino-
phils) infiltrates mainly involving the hepatic acini [7]. The third phase is hepatic fibrosis 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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which generally starts from zone 3 and progresses to bridging fibrosis, cirrhosis of liver and 
hepatocellular cancer. Prognosis depends on the degree of liver fibrosis [8].
2. Purpose
The main purpose of management of NAFLD is to halt the process as soon as it is diagnosed. 
The three main modalities of therapy include lifestyle modification, pharmacotherapy and 
bariatric surgery. Lifestyle modification is applicable to all stages of NAFLD, whereas phar-
macotherapy and bariatric surgery should not be considered for patients with simple steatosis. 
Pharmacotherapy should be considered only for patients with biopsy-proven NASH and hepatic 
fibrosis as per the guideline of American Association for the Study of Liver Diseases (AASLD).
3. Lifestyle modification
As NAFLD is related to insulin resistance, gradual weight loss is extremely important in over-
weight and obese individuals [9]. Rapid weight loss can cause portal inflammation and fibrosis 
[10]. About 7–10% of weight loss over one year by lifestyle changes has been associated with his-
tological improvement in simple steatosis and NASH [11]. Another study showed vigorous and 
moderate exercises were equally effective in reducing hepatic triglyceride content largely through 
weight loss [12]. Diet and moderate aerobic exercise are the first line measures to reduce weight and 
improve insulin resistance [13]. Dietary counseling should be highly encouraged. Consumption 
of high fructose containing food is the main cause of epidemic of obesity [14]. Patient should 
avoid high fructose containing foods like sweet, soda, desserts, breakfast cereals, granola bars and 
cakes. One study showed that in patients with NAFLD, fructokinase and fatty acid synthase activ-
ity are increased [15]. NAFLD may occur when there is a combination of genetic predisposition, 
sedentary life style and consumption of high-calorie foods [16]. One meta-analysis suggested that 
Omega-3 fatty acid supplementation in diet was beneficial in patients with NAFLD/NASH [17]. 
Patients should be encouraged to eat food rich in Omega-3 fatty acid (fish, canola, olive, perilla 
and chia). Food with high glycemic effects and saturated fat should be avoided [18].
In summary, lifestyle modification is the first line intervention in the management of 
NAFLD. This includes [1] weight loss of about 7–10% of body weight by a combination of diet 
and exercise [2], low-calorie diet [3], diet with high fructose and saturated fat should be avoided 
[4], diet with Omega-3 fatty acid supplement should be encouraged.
4. Pharmacotherapy
There are various pharmacological agents available for the management of NAFLD. Many 
of them have been found to be ineffective and some of them have high risk-benefit ratio [19]. 
There are various clinical trials ongoing. Here, we discuss the common agents available and the 
agents recommended by the American Association for the Study of Liver Diseases (ASSLD).
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4.1. Antioxidants
Progression of simple steatosis to steatohepatitis is related to oxidative stress and free rad-
ical formation. Vitamin E has been studied in different clinical trials. One study showed 
that patients with vitamin E deficiency and NAFLD did not respond to the classical diet for 
NAFLD [20]. In PIVENS trial, vitamin E 800 units per day was associated with improvement 
of serum transaminases and liver histology in nondiabetic NAFLD patients [21]. Fibrosis 
scores were not improved in this trial [22]. In SELECT trial, vitamin E supplementation 
400 units per day in healthy individuals was associated with significant increase in prostate 
cancer [23].
Currently, vitamin E 800 units per day is recommended in nondiabetic individuals with 
biopsy-proven NASH [19].
4.2. Insulin sensitizing agents
4.2.1. Thioglitazones (TZD)
They are agonists/selective ligands of nuclear transcription factor PPAR-ϒ (peroxisome 
proliferator-activated receptor-gamma) which is present in pancreatic β-cells, adipocytes, 
skeletal muscles, endothelial cells and macrophages. They increase insulin sensitivity in 
NAFLD and thus, promote fatty acid transportation from liver and skeletal muscles into 
adipose tissue, decrease serum-free fatty acid concentration and increase fatty acid oxida-
tion in the liver [24]. Pioglitazone 30 mg/day improved hepatic steatosis, steatohepatitis 
and transaminitis in nondiabetic patients with NASH in the PIVENS trial but histological 
response did not reach statistical significance [22]. Another study showed that in prediabetic 
and diabetic patients, long-term treatment with pioglitazone 45 mg/day improved not only 
steatotic and inflammatory activity but also hepatic fibrosis [25]. There are few concerns 
about the side effects of TZD and these include weight gain [26], bone loss [27] and conges-
tive heart failure [28].
As pioglitazone improves histology of NASH in both diabetic and nondiabetic individuals, it 
can be used in biopsy-proven NASH. Patients should be informed about the efficacy and side 
effects of this medication.
4.2.2. Incretin-based therapy
Glucagon-like peptide 1 (GLP-1) receptor agonists (liraglutide and exenatide) not only 
improves insulin sensitivity but also causes weight loss by suppressing appetite and inhibit-
ing gastric emptying [29]. They are primarily used to control diabetes mellitus at this time. 
There are case reports of improvement of hepatic steatosis by GLP-1 receptor agonists [30]. 
Another study found that liraglutide given daily improved steatohepatitis and decreased pro-
gression of fibrosis [31].
Although incretin mimetics have been found to be helpful in diabetic patients with NAFLD, 
they are currently not recommended solely to treat NASH or NAFLD [19].




As sustained weight loss is achievable by bariatric surgery, all the features of metabolic syn-
drome improve and there is reduction in mortality [32]. In a prospective study, NASH disap-
peared in 70% (severe NASH) to 94% (mild NASH) of patients 1 year after bariatric surgery 
[33]. There are various bariatric surgical and endoscopic procedures available and approved 
for morbid obesity at the present time. Laparoscopic sleeve gastrectomy is most commonly 
done in the United States [34]. Other surgical procedures include gastric bypass, bilioin-
testinal bypass, biliopancreatic diversion with duodenal switch, vertical band gastroplasty 
and gastric banding. Various endoscopic procedures include intragastric balloon placement, 
endoscopic sleeve gastroplasty [35] and duodenal mucosal resurfacing [36]. Bariatric endos-
copy is successful in reducing more weight than pharmacological agents but less effective 
than bariatric surgery but has less complications than bariatric surgery. Bower et al. found 
in a systematic review of studies that bariatric surgery improved steatosis, steatohepatitis 
and fibrosis in NAFLD [37]. Patients with cirrhosis of liver due to NAFLD are at a higher risk 
for bariatric surgery [38]. Another study showed that perioperative mortality was higher in 
patients with NAFLD with cirrhosis than in patients with NAFLD without cirrhosis [39].
Nowadays, bariatric surgery is not recommended as a primary treatment of NAFLD but it can 
be considered in obese individuals with noncirrhotic NAFLD [19].
4.2.4. Ursodeoxycholic acid (UDCA)
UDCA has cytoprotective effect and can improve serum transaminases in NAFLD but cannot 
alter liver histology [40].
UDCA is not recommended for the treatment of NAFLD or NASH [19].
4.2.5. Omega-3 fatty acids
Although in animal models, omega-3 fatty acid treatment improved hepatic steatosis [41, 42], 
recent studies did not show any significant effect on serum transaminases or liver histology 
[43]. Omega-3 fatty acid is not recommended for the treatment of NAFLD or NASH.
4.2.6. Obeticholic acid (OCA)
OCA is a ligand of farnesoid X receptor (FXR) which is a nuclear receptor present in liver, 
kidneys, intestine and adipose tissue. FXR controls target genes involved in bile acid syn-
thesis and transport as well as lipid and carbohydrate metabolism. In the farnesoid X recep-
tor ligand obeticholic acid in NASH treatment (FLINT) trial, OCA induced weight loss and 
improved hepatic fibrosis but resolution of NASH was not statistically more than placebo. 
OCA decreased serum transaminases but increased serum alkaline phosphatase, LDL and 
blood glucose levels [44].
Currently, OCA is not recommended in the routine management of NAFLD awaiting the 
completion of phase 3 trial (REGENERATE) of OCA for the treatment of NASH patients with 
liver fibrosis [45].
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5. Elafibranor
Elafibranor is an agonist of PPAR-α and δ receptor. It has anti-inflammatory activity and can 
improve insulin sensitivity and lipid metabolism. It was evaluated in a phase II international study 
for the treatment of NASH [46]. In the post hoc analysis, elafibranor (120 mg/day for 1 year) group 
showed resolution of NASH without progression of fibrosis more than placebo (19% vs. 12%).
As the improvement was marginal, further studies are needed before using this agent in the 
treatment of NAFLD.
5.1. Statins
Hyperlipidemia is frequently seen in patients with NAFLD as part of the metabolic syndrome. 
Statins are commonly used for the treatment of hyperlipidemia, and low-to-moderate dose 
of statins have been found to be safe with low hepatic toxicity [47]. Statins decrease hepatic 
transaminases and hepatic fat but have no effect on hepatic fibrosis [48, 49].
Statins are not currently recommended solely for the treatment of NAFLD unless the patient 
has concomitant hyperlipidemia.
5.2. Orlistat
Orlistat is used as a weight reducing agent as it induces fat malabsorption by inhibiting enteric 
and pancreatic lipase [50]. A randomized controlled trial showed that orlistat improved transami-
nitis and hepatitis steatosis in obese individuals with NAFLD [51]. Subsequent study suggested 
that orlistat did not have any direct effect on NAFLD, overweight subjects improved their hepatic 
histology if they achieved ≥5% weight loss irrespective of taking orlistat [52].
Currently, orlistat cannot be recommended primarily for NAFLD.
5.3. NAFLD and cirrhosis
Patients should be managed the same way as in other cirrhosis. Patients with NAFLD-
cirrhosis have 2.6% annual cumulative risk of developing hepatocellular cancer [53]. For every 
6 months, abdominal ultrasound is recommended for screening of hepatocellular carcinoma. 
In obese individuals, if ultrasound is technically difficult, CT or MRI should be considered. 
As obesity and hyperinsulinemia are risk factors for malignancy, liver cancer can occur even 
in noncirrhotic NAFLD [54]. Screening for esophageal and gastric varices should be done at 
base-line of diagnosis of cirrhosis and at regular intervals—no varices: every 2–3 years, small 
varices—every 1–2 years and decompensated cirrhosis—yearly once [55].
With the epidemic of NAFLD, NASH-cirrhosis and hepatocellular carcinoma will be the 
leading indication of liver transplantation in future. As patients with NAFLD have multiple 
metabolic and cardiovascular comorbidities, they should be managed posttransplant appro-
priately. Management of NAFLD involves multiple specialties which include primary care 
physicians, gastroenterologists, hepatologists, endocrinologists, bariatric surgeons, transplant 
surgeons, dietitians and nutritionists.




As hepatic inflammation, fibrosis, cirrhosis and subsequent malignancy are the main concerns of 
NAFLD, plenty of research and studies on anti-inflammatory and anti-fibrotic agents are on-going.
7. Summary
The management of NAFLD patients should be individualized (Table 1).
• Lifestyle change is the first line therapy: healthy food habit, increased physical activity, 
exercise and weight loss of 7–10%.
• Pharmacotherapy is to be considered when lifestyle changes fail to achieve the goal: vitamin 
E in nondiabetic biopsy-proven NASH, pioglitazone in both diabetic and nondiabetic biopsy-
proven NASH, incretin mimetics in diabetes mellitus and NAFLD, statins in hyperlipidemia 
and NAFLD, orlistat in NAFLD and obesity when life-style changes fail to reduce weight loss.
• Bariatric surgery should be considered in obese individuals and noncirrhotic NAFLD.
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